Loading...
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
BACKGROUND: Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the treatmen...
Na minha lista:
| Udgivet i: | Mol Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6456974/ https://ncbi.nlm.nih.gov/pubmed/30971271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-1012-4 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|